ArticleThe Journal of clinical investigation2007
Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells.
Article in The Journal of clinical investigation, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02771197 (Phase II Trial of Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in High Risk AML Patients Who Are Not Eligible for Allogeneic Stem Cell Transplantation), which is not on this map. Cited by 121 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Trial of Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in High Risk AML Patients Who Are Not Eligible for Allogeneic Stem Cell Transplantation
Who cites it
121 citing papers in PubMed, 199 citations in OpenAlex.
- Phase 2 study of PD-1 blockade following autologous transplantation for patients with AML ineligible for allogeneic transplant.Blood advances · 2023Trial
- Trial
- Trial
- Trial
- Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2008Trial
- Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma.Cancer immunology, immunotherapy : CII · 2008Trial
- Dendritic Cell Dysfunction Underlies Immune Escape After Adoptive Cellular Therapy in Glioblastoma.Cancers · 2026Article
- Ex vivo expanded autologous hematopoietic stem cells stimulate improved immunogenic activity: an in-vitro preliminary study for future clinical uses.Molecular biology reports · 2026Article
- Bridging transplantation and immunotherapy: Clinical promise of autologous stem cell transplantation with chimeric antigen receptor T-cell therapy.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Article
- Article
- Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma.Journal for immunotherapy of cancer · 2024Article
- Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment.Cancer research communications · 2023Article
- Cellular Cancer Immunotherapy Development and Manufacturing in the Clinic.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Review
- Immunotherapy reverses glioma-driven dysfunction of immune system homeostasis.Journal for immunotherapy of cancer · 2023Article
- Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle.Frontiers in immunology · 2023Review
- Article
- Review
- The Autologous Hematopoietic Stem Cells Transplantation Combination-Based Chimeric Antigen Receptor T-Cell Therapy Improves Outcomes of Relapsed/Refractory Central Nervous System B-Cell Lymphoma.Journal of oncology · 2022Article
- Gut microbiome in multiple myeloma: Mechanisms of progression and clinical applications.Frontiers in immunology · 2022Review
61 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Depleting host immune elements with nonmyeloablative regimens prior to the adoptive transfer of tumor-specific CD8(+) T cells significantly enhances tumor treatment. In the current study, superior antitumor efficacy was achieved by further increasing the intensity of lymphodepletion to a level that required HSC transplantation. Surprisingly, the HSC transplant and not the increased lymphodepletion caused a robust expansion of adoptively transferred tumor-specific CD8(+) T cells. The HSC-driven cell expansion of effector, but not of naive, CD8(+) T cells was independent of in vivo restimulation by MHC class I-expressing APCs. Simultaneously, HSCs also facilitated the reconstitution of the host lymphoid compartment, including inhibitory elements, not merely via the production of progeny cells but by enhancing the expansion of cells that had survived lymphodepletion. Profound lymphodepletion, by myeloablation or by genetic means, focused the nonspecific HSC boost preferentially toward the transferred tumor-specific T cells, leading to successful tumor treatment. These findings indicate that CD8(+) T cell-mediated tumor responses can be efficiently driven by HSCs in the myeloablative setting and have substantial implications for the design of new antitumor immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.